Abivax

Established: 2013

Country: France

Region: Ile-de-France

Investors: Sofinnova Partners

Sofinnova Partners has supported Abivax on its path to becoming one of Europe’s leading clinical stage biotechs. After its IPO on Euronext Paris in 2015, the company steadily advanced through scientific milestones and, in 2023, listed on Nasdaq. That same year, the appointment of Marc de Garidel as CEO more than doubled Abivax’s share price within a month, reflecting investor confidence in his track record, which includes CinCor Pharma’s IPO and sale to Astra Zeneca for $1.8 billion and Corvidia Therapeutics’ $2.1 billion sale to Novo Nordis.

In 2025, Abivax reported positive Phase 3 data, sending its shares up 600% and supporting a landmark $747.5 million follow-on raise — a milestone that underscores investor appetite for European innovation. The company demonstrates how European biotechs can draw on both U.S. and European markets at the right time, navigating the capital-intensive post-Series B stage with the right leadership, strategy, and preparation. Headquartered in Paris, Abivax continues to advance transformative therapies while positioning itself for long-term growth on Nasdaq or through strategic partnerships.

employees across US and France as of March 31, 2025

$747mn

total raised since US IPO

+600%

stock increase post positive Phase 3 data

Kinam Hong

Partner - Sofinnova Partners

Abivax’s Phase 3 results are more than a clinical milestone – they mark one of the most remarkable comeback stories in European biotech. From strengthening its leadership and pipeline strategy to completing the largest Nasdaq IPO for a European biotech that year, the company has reset and delivered data that could transform the treatment of ulcerative colitis. Sofinnova Partners has supported Abivax throughout this journey, and the company is now well positioned for its next chapter on the global stage.

Marc de Garidel

CEO - Abivax

The positive Phase 3 ABTECT induction trial results are a massive win, not just for Abivax, but for the entire European biotech ecosystem. These results have provided a much-needed boost of confidence for innovative science across the continent. The journey to this point was a tough one, and the sheer scale of global development was often daunting. However, our belief in the potential of obefazimod and our desire to bring it to patients in need fueled us along the way. We owe a special thank you to the small group of dedicated investors, including Sofinnova, who believed in our vision and backed us through those most challenging times. This success is a powerful validation of that shared commitment.